Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D ΔR2-μMRA
- 5 June 2013
- journal article
- Published by Springer Nature in Angiogenesis
- Vol. 16 (4) , 785-793
Abstract
Understanding of structural and functional characteristics of the vascular microenvironment in gliomas and the impact of antiangiogenic treatments is essential for developing better therapeutic strategies. Although a number of methods exist in which this process can be studied experimentally, no single noninvasive test has the capacity to provide information concerning both microvascular function and morphology. The purpose of present study is to demonstrate the feasibility of using a novel three-dimensional ΔR2-based microscopic magnetic resonance angiography (3D ΔR2-μMRA) technique for longitudinal imaging of tumor angiogenesis and monitoring the effects of antiangiogenic treatment in rodent brain tumor models. Using 3D ΔR2-μMRA, a generally consistent early pattern of vascular development in gliomas was revealed, in which a single feeding vessel was visualized first (arteriogenesis), followed by sprouting angiogenesis. Considerable variability of the tumor-associated vasculature was then noted at later stages of tumor evolution. ΔR2-μMRA revealed that anti-vascular endothelial growth factor treatment induced a rapid and significant alteration of the intratumoral angiogenic phenotype. In summary, 3D ΔR2-μMRA enables high-resolution visualization of tumor-associated vessels while simultaneously providing functional information on the tumor microvasculature. It can serve as a useful tool for monitoring both the temporal evolution of tumor angiogenesis and the impact of antiangiogenic therapies.Keywords
This publication has 40 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imagingNature Medicine, 2009
- In Vivo Monitoring of Angiogenesis Inhibitory Treatment Effects by Dynamic Contrast-Enhanced Computed Tomography in a Xenograft Tumor ModelInvestigative Radiology, 2009
- Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancerCancer Chemotherapy and Pharmacology, 2009
- Systemic Therapy for Advanced or Metastatic Colorectal Cancer: National Comprehensive Cancer Network Guidelines for Combining Anti‐Vascular Endothelial Growth Factor and Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies with ChemotherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant GliomaClinical Cancer Research, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapyNeurology, 2006
- Contrast‐enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinomaCancer, 2002